Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine

Maurizio Fava, Rosemarie Mulroy, Jonathan Alpert, Andrew A. Nierenberg, Jerrold F. Rosenbaum

Research output: Contribution to journalArticle

120 Scopus citations

Abstract

Objective: The rate of adverse events following discontinuation of treatment with extended-release venlafaxine was compared with the rate associated with discontinuation of placebo administration. Method: The subjects were 20 outpatients with major depressive disorder who had participated in a multicenter, double-blind, placebo-controlled study of the efficacy of the new extended-release formulation of venlafaxine. Results: During the 3 days after discontinuation of treatment with the study drug, seven (78%) of the nine venlafaxine-treated subjects and two (22%) of the nine placebo-treated patients reported the emergence of adverse events, a statistically significant difference. Conclusions: These results suggest that clinicians discontinuing venlafaxine treatment should consider tapering the medication dose gradually.

Original languageEnglish (US)
Pages (from-to)1760-1762
Number of pages3
JournalAmerican Journal of Psychiatry
Volume154
Issue number12
DOIs
StatePublished - Jan 1 1997
Externally publishedYes

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine'. Together they form a unique fingerprint.

  • Cite this